Bayer announced on Wednesday that it will be collaborating with US laboratory equipment manufacturer Thermo Fisher to develop new companion tests for cancer management.

These high-throughput sequencing (NGS) tools should help identify patients likely to benefit from Bayer's targeted cancer therapies, explains the German group in a press release.

Their cooperation will focus in particular on the Oncomine Dx Express Test, Thermo Fisher's platform for clinical profiling of a tumor mutation from a biopsy in just 24 hours.

This will be combined with the Ion Torrent Genexus Dx sequencer, another of the American group's automated systems, which delivers results in just one day.

Financial terms of the agreement were not specified.

Copyright (c) 2024 CercleFinance.com. All rights reserved.